دورية أكاديمية

Tumor immunogenomic signatures improve a prognostic model of melanoma survival.

التفاصيل البيبلوغرافية
العنوان: Tumor immunogenomic signatures improve a prognostic model of melanoma survival.
المؤلفون: Morales, Leah, Simpson, Danny, Ferguson, Robert, Cadley, John, Esteva, Eduardo, Monson, Kelsey, Chat, Vylyny, Martinez, Carlos, Weber, Jeffrey, Osman, Iman, Kirchhoff, Tomas
المصدر: Journal of Translational Medicine; 2/17/2021, Vol. 19 Issue 1, p1-11, 11p
مصطلحات موضوعية: SURVIVAL analysis (Biometry), BRAF genes, GENETIC regulation, CYCLIN-dependent kinase inhibitor-2A, TUMORS, MELANOMA, PROGNOSTIC models
مستخلص: Background: Tumor mutation burden (TMB) has been associated with melanoma immunotherapy (IT) outcomes, including survival. We explored whether combining TMB with immunogenomic signatures recently identified by The Cancer Genome Atlas (TCGA) can refine melanoma prognostic models of overall survival (OS) in patients not treated by IT.Methods: Cox proportional-hazards (Cox PH) analysis was performed on 278 metastatic melanomas from TCGA not treated by IT. In a discovery and two validation cohorts Cox PH models assessed the interaction between TMB and 53 melanoma immunogenomic features to refine prediction of melanoma OS.Results: Interferon-γ response (IFNγRes) and macrophage regulation gene signatures (MacReg) combined with TMB significantly associated with OS (p = 8.80E-14). We observed that patients with high TMB, high IFNγRes and high MacReg had significantly better OS compared to high TMB, low IFNγRes and low MacReg (HR = 2.8, p = 3.55E-08). This association was not observed in low TMB patients.Conclusions: We report a model combining TMB and tumor immune features that significantly improves prediction of melanoma OS, independent of IT. Our analysis revealed that patients with high TMB, high levels of IFNγRes and MacReg had significantly more favorable OS compared to high TMB patients with low IFNγRes and low MacReg. These findings may substantially improve current melanoma prognostic models. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Translational Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:14795876
DOI:10.1186/s12967-021-02738-0